• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AskBio Appoints Clinical Ops Executives

    SpectrumX Partners With UK Contract Manufacturer

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    SpectrumX Partners With UK Contract Manufacturer

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Catalent to Acquire Metrics Contract Services for $475M
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    UPS to Acquire Healthcare Logistics Provider Bomi Group

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    West Pharmaceutical Makes Strategic Investment in Latch Medical

    “3 Key Trends” with James Park

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Behind Every Successful eCOA Solution is a Robust Scientific Strategy
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Biosynth Carbosynth

    Quotient Sciences

    IDT Biologika

    CMC Pharmaceuticals
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Biosynth Carbosynth

    Quotient Sciences

    IDT Biologika

    CMC Pharmaceuticals
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Pharma Beat

    Tackling TB Resistance

    The TB Alliance is partnering with universities, government agencies, public agencies and a small number of pharma compani

    Tackling TB Resistance
    Related CONTENT
    • Frontida BioPharm Launches Expansion Efforts
    • The FDA and Metrics
    • WHO Lauds India’s Vaccine Safety
    • Could Nuts Ward Off Cancer?
    • Generic Drug Trends
    Adele Graham-King, Contributing Editor05.09.17
    Tuberculosis (TB) is a pandemic disease, which has affected human beings for centuries. Documented through the ancient civilizations of India and China, and traced across the globe through the Middle Ages, the killer infection has been given various different names including ‘consumption’ and the White Plague. Consumption is one of the most common definitions due to the dramatic weight loss that is observed through the loss of appetite and persistent coughing, which are clear signs of the disease.

    Caused by the bacteria Mycobacterium tuberculosis, it’s an infection that is spread between humans by airborne transfer of the bacteria through coughing, sneezing or even just speaking to one another. Historically through the 17th to 19th Centuries it was a disease considered to be a pauper problem with a self-blame image of the working classes who lived in crowded conditions. Combined with the industrial revolution, these conditions provided a perfect environment for the bacterial killer to spread rapidly and effectively. Primarily affecting the lungs, although extra-pulmonary TB can also occur, other clinical observations are night sweats, fever, chills and fatigue.

    It wasn’t until 1944 and the discovery of streptomycin that there was an antibiotic treatment for consumption following many failed efforts of treatment through containment and isolation. This was followed in the 1950s with the development of Isoniazid—a mycobactericidal compound—and the antibiotic Rifampicin in the 1970s. At the same time as pharmacological therapies were emerging, scientists had been actively working to develop vaccines. In 1906 French development scientists created the first effective vaccine aptly named the BCG (Bacille Calmette-Guérin) after the creators. Although this was used in France in the early 1920s it wasn’t taken on board further afield until the late 1940s and 1950s. Ironically, although there have been attempts to find alternative vaccinations, to this day this is still the only vaccine available for the prevention of TB.

    Since the development of the BCG vaccine it has been widely used globally and it’s currently estimated to be delivered to 80% of newly born babies across the world. It had been hoped that it would be feasible to eradicate this awful killer, but although there has been a rapid decline in deaths in the developed world, the World Health Organization (WHO) declared a global health emergency in 1993 and again in Africa in 2005 following resurgence of multidrug resistant strains of the bacteria in the 1980s. In addition, with the arrival of HIV around the same time frame there is now an established link with the risk of developing TB and the virus—it is 26-31 times greater in these patients. Bearing in mind the prevalence of HIV in Africa and other parts of the developing world it’s clear to see why TB has reared its ugly head again with a vengeance.

    Currently, according the WHO, TB remains one of the top 10 causes of death worldwide with 1.4 million deaths attributed to it in 2015 and 10.4 million becoming ill. In the same year almost 90% of cases occurred in 6 countries in Asia and Africa and almost half a million people are suspected of suffering from multidrug resistant TB (MDR-TB) strains.

    Standard treatment regimens generally comprise of four anti-TB drugs—isoniazid, rifampicin and a fluoroquinolone—to be taken over a period of 6 months. Recurrence of the disease is treated by four, if not more effective antibiotics for a period of 18-24 months. However over recent years the bacteria has mutated even more so and newer definitions of extensively drug-resistant TB—XDR-TB is resistant to three or more TB drugs—and in the past 10 years totally drug-resistant TB have emerged. Something has to be done in order to reach the goal of the WHO to beat the world TB epidemic by the end of 2030.

    The TB Alliance is a not-for-profit organization dedicated to the discovery and development of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. It is a funded agency, which relies on support of donors to fund its development work that includes the FDA and USAID. Working in partnership with universities, government agencies, public agencies and a small number of pharma companies, it aims to develop new TB drugs alongside maximizing the treatment regimens of established drug entities. Although TB is still at global pandemic levels there are fewer than 20 known compounds with activity against mycobacterium, which leaves a massive hole in a therapy area where resistance is well known to be increasing.

    One of the established partnerships of the TB Alliance is between John Hopkins University (Baltimore) and the Medicines Patent Pool (MPP), which is a UN-backed organization supporting development and access to medicines for poorer countries in the specific areas of HIV, Hep-C and TB. Of late, the partnership has been working together to clinically develop Sutezolid, a drug candidate which has demonstrated interesting activity in combination with other TB drugs in treatment of the condition. Sutezolid is an oxazolidinone, the same class of drug as linezolid, which is also under investigation by the TB Alliance in early Phase II and Phase III clinical trials. In some ways it’s absurd that there are so few treatment options for TB which is a globally devastating condition, however it looks like the alliance combined with the MPP are making progress.

    In March 2017 the MPP announced a sublicensing agreement for the clinical development of Sutezolid in partnership with the TB Alliance and the patent owner John Hopkins University. Using the combination of the other known licensed drugs that are acknowledged to have activity against the mycobacterium has great potential to provide another treatment against XDR-TB, which is becoming increasingly difficult to combat and unfortunately increasingly common. The license, which the MPP holds now gives them the rights to approach interested parties to investigate the possibilities of developing treatments for both sensitive and resistant TB strains and to look at combinations with other drug entities to create new multi-pronged attacks on the bacteria.

    In line with further work from the TB Alliance who have Phase I, II, III & IV trials ongoing using a mix of pharmaceutical agents including Ethambutol, Pyrazinamide, Isoniazid, Pretomanid, Moxifoxacin, Linezolid and Bedaquiline, the outlook for identifying new treatments looks very positive, regardless of identification of new drug entities. Several of these drugs are listed on the WHO’s List of Essential Medicines and are generic, cost effective medicines with simple routes of administration, which is in line with the TB Alliance strategy to be successful in developing better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. Alongside activities such as the MPP-TB Alliance project, they are hopefully well on track to hit their target of beating TB by 2030.


    Adele Graham-King
    Contributing Editor

    Adele is a design consultant who works in product development for medical and healthcare applications. Her background is in pharma, and she has a degree in applied physiology.
    Related Searches
    • Vaccine
    • clinical development
    • vaccines
    • china
    Suggested For You
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    The FDA and Metrics The FDA and Metrics
    WHO Lauds India’s Vaccine Safety WHO Lauds India’s Vaccine Safety
    Could Nuts Ward Off Cancer? Could Nuts Ward Off Cancer?
    Generic Drug Trends Generic Drug Trends
    The Trials and Tribulations  of Male Contraception The Trials and Tribulations of Male Contraception
    LSNE Completes Two FDA Inspections LSNE Completes Two FDA Inspections
    ‘Smart’ Heparin Delivery Could Self-Modulate ‘Smart’ Heparin Delivery Could Self-Modulate
    FDA’s Quality Agreements Guidance FDA’s Quality Agreements Guidance
    IDT Biologika Establishes Animal Health Biz in U.S. IDT Biologika Establishes Animal Health Biz in U.S.
    Trends Affecting the Generic Drugs Sector in 2017 Trends Affecting the Generic Drugs Sector in 2017
    Novasep Custom Mfg. Sites Complete FDA Inspections Novasep Custom Mfg. Sites Complete FDA Inspections
    Genentech Extends Phylogica Research Pact Genentech Extends Phylogica Research Pact

    Related Breaking News

    • Breaking News | Facilities | Industry News | Inspections
      Frontida BioPharm Launches Expansion Efforts

      Frontida BioPharm Launches Expansion Efforts

      Comes on heels of receiving FDA clearance
      05.26.17

    • Regulatory Affairs
      The FDA and Metrics

      The FDA and Metrics

      The Agency and industry continue to work together to achieve FDA’s objectives
      David Lonza, Lachman Consultant Services, Inc. 05.09.17

    • WHO Lauds India’s Vaccine Safety

      The World Health Organization endorses India’s regulation of vaccines even as desi players try their hands in more advanced v
      S. Harachand, Contributing Editor 04.03.17


    • Drug Development

      Could Nuts Ward Off Cancer?

      Recent research looks into the anti-cancer properties of various nuts
      Adele Graham-King, Contributing Editor 04.03.17

    • Capsules | Solid Dosage/Semi-solids

      Generic Drug Trends

      Industry faces tighter capacity, consolidation, and drug pricing uncertainty
      Edward S. Price, President, PCI 03.07.17

    Loading, Please Wait..
    Trending
    • Almac Invests $65M To Expand North American HQ
    • Just – Evotec Biologics And Alpine Immune Sciences Expand Partnership
    • West Pharmaceutical Makes Strategic Investment In Latch Medical
    • AskBio Appoints Clinical Ops Executives
    • Catalent To Acquire Metrics Contract Services For $475M
    Breaking News
    • AskBio Appoints Clinical Ops Executives
    • GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    • SpectrumX Partners With UK Contract Manufacturer
    • Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership
    • Almac Invests $65M to Expand North American HQ
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    What are you Reading this Week?
    SONGWON Industrial Group Reports Strong Q2 Financial Results
    PPG Completes COLORFUL COMMUNITIES Project for Boys & Girls Clubs of Greater Houston
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Aug. 13
    'Graft-on-a-Chip' Built to Improve Vascular Graft Success
    Abbott Invests €440 in New Irish Facility
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AskBio Appoints Clinical Ops Executives
    SpectrumX Partners With UK Contract Manufacturer
    GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Arkay Chairman Emeritus Howard Kaneff Has Died
    Nutricosmetics Market to Hit $13.7 Billion by 2030
    Estée Lauder Pledges 100% Electric Fleet of Vehicles by 2030
    Happi

    Latest Breaking News From Happi

    Consumers are Clamoring for Vintage Glam: Spate
    Kayali’s Lovefest Fragrance, Newell’s New Candle and HydraFacial’s Record Financial Results
    Self Care Trumps Home Care Post-Covid
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Printing Ink Primer, Zeller+Gmelin Lead This Week’s News Stories
    Heidelberg Enjoys Successful Start to 2022-23 Fiscal Year
    Mimaki Announces New LATAM Website
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Esko, Constantia Flexibles announce acquisitions and more
    Hybrid Software joins The Flexo Xperience Center
    Flexo Wash LLC and Mike Potter celebrate 20 years
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Essity Switches to Recyclable Packs for Feminine Pads, FTC Sues PPE Maker on False Origin Claims & More
    Focke & Co. to Host Destination: Your Hygiene Hub on August 31
    Exports Dominate Chinese Trade of Tissues, Hygiene Products and Wipes
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Aug. 13
    Dental 3D Printing Market is Expanding 20% Annually
    Study Results Released for Abbott's Concussion Blood Test
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: ALTANA, Universal Display and Emerson Top This Week’s Stories
    eMagin Corporation Announces 2Q 2022 Results
    Zebra Technologies’ Emission Reduction Targets Validated by SBTi

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login